A follow-up to Between Pain and Policy: How Veterans Are Navigating Cannabis Use
When I wrote Between Pain and Policy, the central argument was simple: veterans are already navigating alternative treatments for PTSD, chronic pain, and sleep disruption and the federal system hasn’t caught up. Cannabis was the lens. The problem is bigger than that.
This week, the alternative treatment argument got stronger.
President Trump is expected to sign an executive order in the coming days directing federal agencies to fund research into ibogaine, a psychoactive compound derived from the iboga plant in Central Africa, with a specific focus on its potential to treat PTSD and traumatic brain injuries in veterans. The order will not reschedule ibogaine from its current Schedule I classification, but it is designed to open the door to serious federal funding and study for the first time.
For veterans who have been quietly traveling overseas to receive this treatment because it isn’t available here, that is not a small thing.
What Ibogaine Is – and Isn’t
Ibogaine is not a recreational drug. It is a powerful psychoactive substance with a documented history of use in addiction treatment, particularly for opioid withdrawal, in countries where it is legal. In recent years, it has drawn serious attention as a potential treatment for PTSD, depression, anxiety, and TBI…conditions that overlap heavily with what the veteran population carries home from service.
Veterans who have pursued ibogaine treatment typically describe an intense, multi-phase experience: an initial visual phase lasting one to four hours, followed by an extended introspective phase that can stretch for several hours to days. Those who come out the other side often describe meaningful reductions in symptoms that traditional medications never touched.
The most cited research to date is a small Stanford Medicine study published in 2024 involving 30 Special Operations veterans who received ibogaine paired with intravenous magnesium…the magnesium used specifically to reduce cardiac risk. The results were incredible: symptoms of PTSD, depression, and anxiety dropped sharply within one month, and no serious cardiac events were reported. High-profile advocates including former Texas Governor Rick Perry, former Senator Kyrsten Sinema, and podcast host Joe Rogan have pointed to studies like this as reason to move faster.
But the researchers themselves were clear: 30 people, no placebo group, no blinding, one month of follow-up. Promising. Not proof.
The Risk Is Real
This is where the story gets harder to tell — and where I think honest journalism matters most.
Ibogaine can cause dangerous heart rhythm disturbances. That is not a fringe concern or a bureaucratic technicality. A 2023 review of 24 studies covering 705 people found evidence of reduced withdrawal symptoms — but also flagged cardiac toxicity as a serious and potentially fatal risk. At least 27 people have died after taking ibogaine. The international clinics where Americans currently receive it operate with no standardized cardiac screening, no required monitoring protocols, and no obligation to report adverse events.
Veterans traveling to Mexico, Europe, or elsewhere for ibogaine treatment are doing so with real hope — and real exposure to a system that cannot protect them the way a regulated medical environment would. The executive order does not change that today. It acknowledges, finally, that science is running behind practice.
That gap — between what veterans are already doing and what federal policy allows — is exactly the same gap I wrote about with cannabis. Different compound. Same broken system. Same veterans caught in the middle.
Where Things Stand
Texas has already moved. Governor Greg Abbott signed legislation last year approving $50 million for ibogaine research — one of the most significant state-level investments in alternative veteran treatment in recent memory. A group of nine veterans featured on 60 Minutes traveled to a remote village near Puerto Vallarta, Mexico, for a week-long psychedelic retreat to address combat-related trauma. Bipartisan congressional lawmakers have introduced legislation to establish psychedelic-focused centers at VA facilities — covering ibogaine, psilocybin, and MDMA.
HHS Secretary Robert F. Kennedy Jr. has said the administration is eager to create a pathway for psychedelic-assisted therapy and wants to move quickly. Whether that urgency translates to the kind of rigorous, properly funded clinical trials that could actually establish safe protocols remains to be seen.
What is clear is that the conversation has changed. A year ago, ibogaine for veterans was a niche story covered mostly in advocacy circles. Today it is the subject of a presidential executive order.
What This Means for Veterans Right Now
If you are a veteran considering ibogaine, this executive order does not make it legal or safe to pursue without medical oversight. The cardiac risks are real and they require proper screening. Anyone pursuing this treatment at an overseas clinic should research the facility’s cardiac protocols thoroughly — and should not go alone.
If you are a veteran who has already pursued ibogaine treatment — or is currently weighing it alongside cannabis, psilocybin, or other alternatives — your experience is part of this story. Smoke-N-Focus Media wants to hear it. The policy conversation needs your voice in it, not just the statistics.
The pattern I keep documenting is the same: veterans are making real decisions in real time, often with inadequate information and no federal support, while policy discussions happen years behind them. Cannabis. Now ibogaine. The substance changes. The gap stays the same.
That gap needs to close. And until it does, Smoke-N-Focus will keep putting a light on it.
📖 Read the original investigation: Between Pain and Policy: How Veterans Are Navigating Cannabis Use
📬 Have a story to share? Reach out here.
AI Use Disclosure
Artificial intelligence tools were used in a limited support role during the development of this piece for organizational assistance and editing suggestions. All reporting context, source selection, factual verification, analysis, and editorial judgment were conducted by the author. Statistics and policy information were independently verified using primary and credible secondary sources. All conclusions reflect the author’s original reporting and reasoning.
